Shots: The CDC’s ACIP has voted to recommend Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) to protect adults against invasive disease and pneumonia caused by the 20 S. pneumoniae serotypes The […]readmore
Tags : Pneumonia
Shots: The approval is based in the clinical program including P-I & II trials, and three P-III trials evaluating the safety & immunogenicity of Prevnar 20 in adults aged ≥18yrs. […]readmore
Shots: The P-III SAVE-MORE study involves assessing the efficacy and safety of anakinra (100mg/day, SC for up to 10 days) + SoC guided by suPAR vs PB0 + SOC in […]readmore
Shots: The P-III REMDACTA study involves assessing Actemra/RoActemra (tocilizumab) + Veklury (remdesivir) vs PBO + Veklury in hospitalized patients with severe COVID-19 pneumonia receiving SOC The study did not meet […]readmore
Shots: The P-III EMPACTA study involves assessing of Actemra + SOC vs PBO + SOC in 389 patients aged > 18yrs. with confirmed SARS-CoV-2 (COVID-19) infection with SpO2 <94% while […]readmore
Shots: GSK will initiate a clinical trial to evaluate its RA drug, otilimab on patients suffering from pneumonia related to COVID-19 at the end of May’2020. The study will evaluate […]readmore
Shots: Chugai has filed a clinical trial notification with the PMDA to conduct a P-III clinical study of Actemra (tocilizumab, IV, 80mg/200mg/400mg) to treat hospitalized patients with severe COVID19 pneumonia […]readmore
Shots: The P-III OPTIC and OASIS-1 studies involves assessing of Nuzyra (Omadacycline) vs moxifloxacin & linezolid in 386 & 645 patients with community acquired bacterial pneumonia (CABP) & acute bacterial […]readmore